Latest Safety News

Volt Group Limited reported a robust 20% increase in FY24 revenue receipts, driven by strong EcoQuip growth and strategic contract wins, while advancing its zero-emission ATEN technology with promising trials underway.

Sayona Mining’s December 2024 quarterly report reveals robust operational gains at North American Lithium, a successful $38 million capital raise, and a transformative merger agreement with Piedmont Lithium.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

Brightstar Resources has consolidated its position as a rising gold producer with key acquisitions expanding its resource base beyond 3 million ounces and the commencement of ore haulage under a new processing agreement. The company’s December quarter report outlines a robust production growth strategy supported by a $30 million capital raise and ongoing exploration success.

SRJ Technologies reported a remarkable 178% increase in Q4 FY24 cash receipts, driven by strong contract activity and strategic partnerships, including a key Middle East market entry. Despite some project delays, the company remains confident in its growth trajectory for FY25.

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Hastings Technology Metals has secured a strategic non-binding MOU with Saudi Arabia’s Ministry of Investment to explore a rare earths processing facility, while reporting encouraging developments at its Yangibana Project and maintaining solid financial footing.

Jameson Resources Limited has made significant progress in environmental approvals for its Crown Mountain Hard Coking Coal Project, while community and political backing for the coal sector in Canada strengthens. The company plans to resubmit its Environmental Impact Statement by mid-2025.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Galena Mining Limited reports a challenging December quarter at its 60%-owned Abra Base Metals Mine, marked by production declines and ongoing voluntary administration. The company appoints a new CEO for Abra and explores recapitalisation options to stabilise operations.

Carbine Resources reports steady progress on its Muchea West silica sand mining licence application, engaging environmental consultants to support upcoming approvals. The company also continues exploration efforts at its Down South project.